Century Therapeutics, Inc.
IPSC
$0.52
-$0.0018-0.35%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 427.56% | 2.59% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 427.56% | 2.59% | |||
| Cost of Revenue | 7.89% | 0.03% | |||
| Gross Profit | 4.67% | 0.05% | |||
| SG&A Expenses | 9.09% | 0.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.17% | 0.15% | |||
| Operating Income | 1.37% | -0.10% | |||
| Income Before Tax | -9.81% | -0.16% | |||
| Income Tax Expenses | 22,300.00% | -136.36% | |||
| Earnings from Continuing Operations | -15.52% | -0.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.52% | -0.06% | |||
| EBIT | 1.37% | -0.10% | |||
| EBITDA | 1.58% | -0.63% | |||
| EPS Basic | -14.57% | 3.03% | |||
| Normalized Basic EPS | 0.56% | 2.91% | |||
| EPS Diluted | -14.57% | 3.03% | |||
| Normalized Diluted EPS | 0.56% | 2.91% | |||
| Average Basic Shares Outstanding | 0.84% | 3.18% | |||
| Average Diluted Shares Outstanding | 0.84% | 3.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||